Feedback
Settings

Settings

Goto Application

1. WO2014061827 - TREATMENT OF PULMONARY FIBROSIS USING AN INHIBITOR OF CBP/CATENIN

PermaLink
Publication Number WO/2014/061827
Publication Date 24.04.2014
International Application No. PCT/JP2013/079056
International Filing Date 21.10.2013
IPC
A61K 31/5365 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5365ortho- or peri-condensed with heterocyclic ring systems
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
CPC
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
53having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5365ortho- or peri-condensed with heterocyclic ring systems
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
Applicants
  • PRISM PHARMA CO., LTD. [JP]/[JP]
Inventors
  • KOUJI, Hiroyuki
  • ODAGAMI, Takenao
Agents
  • TAKASHIMA, Hajime
Priority Data
61/716,06919.10.2012US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF PULMONARY FIBROSIS USING AN INHIBITOR OF CBP/CATENIN
(FR) TRAITEMENT DE LA FIBROSE PULMONAIRE À L'AIDE D'UN INHIBITEUR DE LA CBP/CATÉNINE
front page image
Abstract
(EN) The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of pulmonary fibrosis, including usual interstitial pneumonia and idiopathic pulmonary fibrosis, and pharmaceutical compositions comprising such alpha helix mimetic β-catenin inhibitors.
(FR) La présente invention concerne d'une manière générale des structures mimétiques d'hélice alpha, et plus particulièrement des structures mimétiques d'hélice alpha qui sont des inhibiteurs de la β-caténine. L'invention concerne également des applications dans le traitement de la fibrose pulmonaire, y compris la pneumonie interstitielle ordinaire et la fibrose pulmonaire idiopathique, et des compositions pharmaceutiques comprenant de tels inhibiteurs mimétiques d'hélice alpha de la β-caténine.
Related patent documents
US20160166577
EP2908820
Latest bibliographic data on file with the International Bureau
# -